 |
| Company |
Product name
/number |
Product
type |
Phase of development |
Status and
comment
(October 1998) |
| PC |
I |
II |
III |
L |
|
| Abbott |
ABT -431 |
D1-selective agonist |
 |
 |
 |
|
|
Pro-drug of the D1 agonist
A-86929 with greater chemical stability |
|
| Amgen |
GDNF |
Glial cell
line-derived neurotropic factor |
|
|
|
|
|
A nerve cell
growth factor |
| FKBP |
neuroimmunophilin |
|
|
|
|
|
New class
of compound that stimulates nerve regeneration and repair |
|
| Astra Medica |
Selagiline |
MAO-b inhibitor |
|
|
|
 |
 |
|
|
| Astra Charnwood |
Remacemide |
NMDA channel
blocker |
|
|
|
|
|
|
|
| Athena Neurosciences |
Selegiline |
MAO-B inhibitor |
|
|
|
|
|
Rapid dissolving
formulation |
|
| Boehringer
Ingelheim |
Talipexale |
D3 agonist
|
|
|
|
|
|
Available
in Japan |
|
| Bristol-Myers
Squibb |
Brasofensine |
Dopamine
uptake inhibitor |
|
|
|
|
|
|
| NS2214 |
D and noradrenaline
uptake blocker |
|
|
|
|
|
In collaboration
with Neurosearch (Denmark) |
|
| Britannia |
Apomorphine |
D agonist |
|
|
|
|
|
Injectable
formulation for 'on-off' Parkinson's |
|
| Cambridge
Laboratories |
Lysuride maleate |
Dopamine
agonist |
|
|
|
|
|
|
|
| Du Pont |
Levodopa +
Carbidopa |
Dopamine
+ DD inhibitor |
|
|
|
|
|
Also available
in controlled-release form |
|
| Gensia |
GP-3269 |
Adenosine
regulating agent |
|
|
|
|
|
|
|
| Glaxo wellcome |
Procyclidine |
Aticholinergic |
|
|
|
|
|
|
|
| Knoll |
Biperiden |
Aticholinergic |
|
|
|
|
|
|
|
| Lilly |
Olanzapine |
Pleuripotent
antagonist of D and 5-HT receptors |
|
|
|
|
|
In preliminary
trails for Parkinson's |
| Pergolide |
D1 and D2
agonist |
|
|
|
|
|
Used as an
add-on to levodopa |
| Lilly with
Elan Pharma |
Pergolide |
D1 and D2
agonist |
|
|
|
|
|
Novel delivery
of pergolide |
|
| Lundbeck |
LU 02-584/CPI
1189 |
Free radical
scavenger |
|
|
|
|
|
May reduce
oxidatve strees |
|
| Merck Sharp
& Dohme |
Benztropine |
Antichlinergic |
|
|
|
|
|
|
|
| Novartis |
Amantadine |
D-receptor
agonist |
|
|
|
|
|
|
| Bromocriptine
mesylate |
D agonist |
|
|
|
|
|
|
|
| Orion |
Selegiline |
MAO-B inhibitor |
|
|
|
|
|
|
| Entacapone
(OR-611) |
COMT-inhibitor |
|
|
|
|
|
Add-on treatment
to levopeda and DD inhibitors. Launch due 1998 |
|
| Oxford Biomedica |
Viral vectors |
Foe gene
therapy |
|
|
|
|
|
Will target
TH and DD genes to brain cells |
|
| Pfizer |
CP-101606 |
Selective
NMDA antagonist |
|
|
|
|
|
In Phase II
trails for head trauma |
| CP -283097 |
|
|
|
|
|
|
New pre-clinical
lead with potential in Parkinson's |
|
| Pharmacia
& Upjohn |
Cabergoline |
D2 receptor
agonist |
|
|
|
|
|
|
| Pramipexole |
D2 receptor
agonist |
|
|
|
|
|
Licence expected
during 1998 |
| U-95667E |
Selective
D2 agonist |
|
|
|
|
|
|
|
| Rhone-Poulenc
Rorer |
Riluzole |
Glutamate
antagonist |
|
|
|
|
|
Also has potential
use in other CNS disorders |
|
| Roche |
Levodopa +
Benzerazide |
Dopamine
+ DD inhibitor |
|
|
|
|
|
Also marketed
in dispersible and controlled-release forms |
| Tolcapone |
COMT inhibitor |
|
|
|
|
|
Adjunct to
levodopa + benserzide or levidopa + carbidopa |
|
| Scherer DDS |
Apomorphine |
D agonist |
|
|
|
|
|
Fast dissolving
formulation for late-stage Parkinson's |
| Selegiline |
MAO-B inhibitor |
|
|
|
|
|
Rapid dissolving
formulation |
|
| SmithKline
Beecham |
Ropinirole |
D2 agonist |
|
|
|
|
|
Licensed for
use both alone and in combination with levodopa |
|
| Lorex Synthelabo |
SL-34.0026 |
MAO-B inhibitor |
|
|
|
|
|
|
|
| Wyeth Laboratories |
Benzhexol |
Anticholinergic |
|
|
|
|
|
Also marketed
by Bioglan in the UK |
|
| Yamanouchi |
Orphendrine |
Anticholinergic |
|
|
|
|
|
Also marketed
by 3M Healthcare and Bioglan |
|
